Biosimilar Biological Product Review Streamlining

Current understanding

To be populated as evidence accumulates.

2026-04-16 — Ensuring Access to Lower-Cost Medicines for Seniors Act: cross-connection with ensuring-access-lower-cost-medicines-seniors-act: Both address biosimilar market access — one by streamlining FDA review, the other by requiring Part D formulary/UM parity so approved biosimilars reach patients on equal footing with reference biologics. (novelty: 3)
2026-07-21 — Affordable Prescriptions for Patients Act: 2026 — Affordable Prescriptions for Patients Act (introduced): complements FDA biosimilar review reforms by targeting the patent-litigation side of biosimilar market entry, capping assertable reference-product patents (especially late-filed patents) in BPCIA proceedings. (novelty: 2) (novelty: 2)
2026-07-21 — A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.: 2026-07-21 — S5059 (119th Congress, introduced): Senate bill referred to HELP Committee that would amend the Public Health Service Act to streamline FDA review of biosimilar biological products; no substantive procedural mechanism disclosed at introduction. (novelty: 2)